These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 10438378)

  • 21. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
    Lori F; Lisziewicz J
    Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute HIV infection.
    Perrin L; Yerly S
    J Biol Regul Homeost Agents; 1995; 9(3):95-9. PubMed ID: 8782015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfer of antivirals to skin Langerhans cells--a novel approach to anti-HIV treatment by "antiviral peplotion".
    Becker Y
    Acta Biochim Pol; 1996; 43(1):175-81. PubMed ID: 8790722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
    Uglietti A; Maserati R
    Expert Opin Investig Drugs; 2011 Apr; 20(4):559-65. PubMed ID: 21391888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
    De Boer RJ; Boucher CA; Perelson AS
    AIDS; 1998 Sep; 12(13):1567-70. PubMed ID: 9764774
    [No Abstract]   [Full Text] [Related]  

  • 31. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New concepts in the immunopathogenesis of HIV infection.
    Graziosi C; Pantaleo G
    J Biol Regul Homeost Agents; 1995; 9(3):73-5. PubMed ID: 8782009
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of treating co-infections on HIV-1 viral load: a systematic review.
    Modjarrad K; Vermund SH
    Lancet Infect Dis; 2010 Jul; 10(7):455-63. PubMed ID: 20610327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus associated changes in germinal centers of lymph nodes and relevance to impaired B-cell function.
    Tenner-Racz K
    Lymphology; 1988 Mar; 21(1):36-43. PubMed ID: 3294513
    [No Abstract]   [Full Text] [Related]  

  • 35. Hydroxyurea in the treatment of HIV-1.
    Gibbs MA; Sorensen SJ
    Ann Pharmacother; 2000 Jan; 34(1):89-93. PubMed ID: 10669190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.
    Zackin R; Marschner I; Andersen J; Cowles MK; De Gruttola V; Hammer S; Fischl M; Cotton D
    J Infect Dis; 1998 Mar; 177(3):761-5. PubMed ID: 9498459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.